Cover Image

Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model

Abstract Molibresib (GSK525762) is an investigational, orally bioavailable, small‐molecule bromodomain and extraterminal (BET) protein inhibitor for the treatment of advanced solid tumors. Molibresib was initially evaluated in a first‐time‐in‐human (FTIH) study BET115521 consisting of two parts: Par...

Full description

Saved in:

Bibliographic Details
Main Authors:	Anu Shilpa Krishnatry (Author), Alexander Voelkner (Author), Arindam Dhar (Author), Marita Prohn (Author), Geraldine Ferron‐Brady (Author)
Format:	Book
Published:	Wiley, 2021-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors
by: Anu Shilpa Krishnatry, et al.
Published: (2022)

A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS‐114
by: Hikari Araki, et al.
Published: (2022)

Bridging population pharmacokinetic and semimechanistic absorption modeling of APX3330
by: Larissa L. Silva, et al.
Published: (2024)

Semimechanistic pharmacokinetic-pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy
by: Soyoung Lee, et al.
Published: (2023)

Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin
by: Ali A. Alhadab, et al.
Published: (2020)

Semimechanistic models to relate noxious stimulation, movement, and pupillary dilation responses in the presence of opioids
by: Nicolás Marco‐Ariño, et al.
Published: (2022)

Importance of Stability Analysis When Using Nonlinear Semimechanistic Models to Describe Drug‐Induced Hematotoxicity
by: Chiara Fornari, et al.
Published: (2020)

Semimechanistic modeling of copeptin and aldosterone kinetics and dynamics in response to rehydration treatment for diabetic ketoacidosis in children
by: Marije E. Otto, et al.
Published: (2023)

Semimechanistic Clearance Models of Oncology Biotherapeutics and Impact of Study Design: Cetuximab as a Case Study
by: Ana‐Marija Grisic, et al.
Published: (2020)

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
by: Samit R. Joshi, et al.
Published: (2020)

Semimechanistic Pharmacodynamic Modeling of Aztreonam‐Avibactam Combination to Understand Its Antimicrobial Activity Against Multidrug‐Resistant Gram‐Negative Bacteria
by: Alexia Chauzy, et al.
Published: (2019)

Editorial: Pharmacokinetic Evaluation and Modeling of Clinically Significant Drug Metabolites
by: Constantin Mircioiu, et al.
Published: (2021)

SOLUBLE EXPRESSION OF SYNTHETIC CSF3syn GENE FUSED WITH THIOREDOXIN IN Escherichia coli BL21(DE3) THROUGH AUTOINDUCTION METHOD AND PURIFICATION
by: Riyona Desvy Pratiwi, et al.
Published: (2015)

Translation of the efficacy of antibody-drug conjugates from preclinical to clinical using a semimechanistic PK/PD model: A case study with RC88
by: Qiaoning Li, et al.
Published: (2023)

Parent-Metabolite Pharmacokinetic Modeling of Formononetin and Its Active Metabolites in Rats after Oral Administration of Formononetin Formulations
by: Ju Hee Kim, et al.
Published: (2022)

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
by: Chetan Rathi, et al.
Published: (2021)

Editorial: Pharmacokinetic evaluation and modeling of clinically significant drug metabolites, Volume II
by: Momir Mikov, et al.
Published: (2023)

Physiologically‐based pharmacokinetic modeling of remdesivir and its metabolites in pregnant women with COVID‐19
by: Xiaomei I. Liu, et al.
Published: (2023)

Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects
by: Xin Luo, et al.
Published: (2024)

Pharmacokinetic modeling of R and S‐Methadone and their metabolites to study the effects of various covariates in post‐operative children
by: Blessed W. Aruldhas, et al.
Published: (2021)

A physiologically-based pharmacokinetic model of oseltamivir phosphate and its carboxylate metabolite for rats and humans
by: Guanghua Gao, et al.
Published: (2019)

A Physiologically Based Pharmacokinetic Model of Ketoconazole and Its Metabolites as Drug-Drug Interaction Perpetrators
by: Fatima Zahra Marok, et al.
Published: (2023)

Population pharmacokinetic model for oral ORIN1001 in Chinese patients with advanced solid tumors
by: Xiaoqing Li, et al.
Published: (2024)

Isolation gidazepam and its metabolites by solid-phase extraction
by: M. A. Savchenko
Published: (2018)

Pharmacokinetics and Main Metabolites of Anwulignan in Mice
by: Cong Chen, et al.
Published: (2022)

Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is it Worth It?
by: M Tod, et al.
Published: (2017)

Physicochemical Characterizations and Pharmacokinetic Evaluation of Pentazocine Solid Lipid Nanoparticles against Inflammatory Pain Model
by: Zaheer Ullah Khan, et al.
Published: (2022)

A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2(−)/(+) populations
by: Claire Steinbronn, et al.
Published: (2023)

Population pharmacokinetic modeling of GS‐441524, the active metabolite of remdesivir, in Japanese COVID‐19 patients with renal dysfunction
by: Asami Sukeishi, et al.
Published: (2022)

Response to "Quantitative Prediction of Drug‐Drug Interactions Involving Inhibitory Metabolites by Physiologically Based Pharmacokinetic Models: Is It Worth?"
by: IE Templeton, et al.
Published: (2017)

Population Pharmacokinetic Modeling and Simulation of TQ-B3101 to Inform Dosing in Pediatric Patients With Solid Tumors
by: Fen Yang, et al.
Published: (2022)

Application of a Physiologically Based Pharmacokinetic Model to Develop a Veterinary Amorphous Enrofloxacin Solid Dispersion
by: Kaixiang Zhou, et al.
Published: (2021)

Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma
by: Jon Collins, et al.
Published: (2023)

Local Irradiation Modulates the Pharmacokinetics of Metabolites in 5-Fluorouracil-Radiotherapy-Pharmacokinetics Phenomenon
by: Ju-Han Liu, et al.
Published: (2020)

Physiologically Based Pharmacokinetic Modeling of Transdermal Selegiline and Its Metabolites for the Evaluation of Disposition Differences between Healthy and Special Populations
by: Santosh Kumar Puttrevu, et al.
Published: (2020)

Clinical Pharmacology of Vinpocetine: Properties Revisited and Introduction of a Population Pharmacokinetic Model for Its Metabolite, Apovincaminic Acid (AVA)
by: Zvonimir Petric, et al.
Published: (2023)

Mining Small Routine Clinical Data: A Population Pharmacokinetic Model and Optimal Sampling Times of Capecitabine and its Metabolites
by: Esther Oyaga-Iriarte, et al.
Published: (2019)

Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors
by: Weize Huang, et al.
Published: (2022)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
by: Kiss B, et al.
Published: (2019)

Intracellular pharmacokinetic study of zidovudine and its phosphorylated metabolites
by: Lingli Mu, et al.
Published: (2016)